Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_assertion type Assertion NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_head.
- NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_assertion wasGeneratedBy ECO_0000203 NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_provenance.
- NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_assertion wasDerivedFrom befree-2016 NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_provenance.
- NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_assertion SIO_000772 15248218 NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_provenance.
- NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_assertion evidence source_evidence_literature NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_provenance.
- NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_provenance.